FH Week 2 September 20, 2018
 

FH WEEK - What are the challenges & priorities? Listen to our Experts on FH

Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require effective initiatives and policies and reduce the burden of disease.

Experts on FH: How is the situation for FH patients in different countries?

EAS FHSC National Leads on the situation for FH patients their respective country and what is their top priority for improvement.

To be published next week, September 24: FHSC publication - a survey of FH care in over 60 countries worldwide

FHSC’s new publication “Overview of the current status of Familial Hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)” was accepted for publication on Atherosclerosis at the beginning of September 2018 (DOI: 10.1016/j.atherosclerosis.2018.08.051).

This global systematic survey uniquely provides an extensive overview of the current status of FH patient management in over 60 contributing countries worldwide.

A comprehensive summary of the latest available information, this landmark article provides international comparisons, and highlights gaps in knowledge, variations from one region/country to another, and initiatives currently ongoing related to FH patient care.

The Open Access paper will be available via Atherosclerosis Journal, and on EAS FHSC web next week.

 

About FH Studies Collaboration:

The mission of the FH Studies Collaboration is to empower the medical and global community to seek change in their respective countries or organisations regarding how FH is detected and managed with a view to promoting early diagnosis and more effective treatment of this condition. Improvement of the management of this condition will improve the lives of patients and empower the medical community to achieve a global policy change.

As per September 2018, the FH Registry includes more than 11,000 cases from 25 countries in the world. FH Studies Collaboration can offer country representatives:

  • support to establish or develop an FH registry in their country
  • inclusion in a global network of FH experts who share experience and information
  • participation in the EAS annual congress and focused FHSC meeting
  • information and eduational materials on FH
  • support to awareness-raising activities at national level among health care professionals and the wider scientific community


Listen to the Experts on FH - more Q&As >>
 Read more about the FHSC Registry >>
Is there a representative in my country? >>

MORE ABOUT EAS AND FH

ABOUT FH WEEK

EXPERTS ON FH - video interviews

FHSC - A worldwide network on FH

FIND A FH CONTACT IN YOUR COUNTRY

HICCS REGISTRY

SPECIAL CLINIC - REFERRAL CENTERS; Genetic testing for FH

FH WEEK NEWSLETTERS

 

EAS - EDUCATION, RESOURCES AND TOOLS

EAS ACADEMY: Certificate of Excellence in FH, EAS Certificate in FH

EAS ACADEMY: Video presentations on FH and related topics (108)

FH SCORE APP

FH HANDBOOK: For Iphone & Ipad :: For Android phone :: For Android Tablet

PUBLICATIONS

UPCOMING FH EVENTS

 

FH Week is an initative by the European Atherosclerosis Society, in cooperation with the FH Studies Collaboration.

FH Week 2018 and "Experts on FH" is a campaign to highlight the importance of a better understanding of Familial Hypercholesterolaemia (FH) and the need for action to improve management of this condition and improve the lives of patients. Although EAS has a special focus on FH this week, efforts to put FH on the public health agenda goes on throughout the year


Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)

Visit: eas-society.org

About this email

FH Week is an initative by the European Atherosclerosis Society. You have received this email because you are currently subscribed to receive general correspondence from EAS, either through membership, attending an EAS event, or registering to one of the Society’s educational activities.

  

European Atherosclerosis Society
Mässans Gata 10
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@

 

European Atherosclerosis Society © 2018